Dr. Bernard Peperstraete is President and CEO of Acuamark Diagnostics, a company he co-founded out of the Barany Labs at Cornell University, which focuses on developing a highly accurate, scalable, and cost-effective test for early detection of cancer out of blood. Members of the academic team are the original inventors of the Ligase Detection Reaction, Ligase Chain Reaction, Universal array, zipcoding and rt-PCR assays.
Until early 2015, Bernard was a Partner at NGN Capital, a firm investing in mid- to late-stage healthcare ventures. At NGN, Bernard was closely involved with the Exosome Diagnostics (Board Observer), Noxxon AG and Artisan Pharmaceuticals (acquired by AKP) transactions, and as Acting CEO/President with ACT Biotech (acquired by Eddingpharm). Bernard previously served as a Director at Potentia Pharmaceuticals (Alcon/Apellis Pharma).
Prior to NGN, Bernard served at Masa Life Science Ventures, where he focused on early stage life science investments. His previous life science operating roles include hospital manager, medical entrepreneur, sales and marketing executive and physician. In 2004, Bernard worked at Novartis where he evaluated the commercial market potential for emerging indications.
Before completing his MBA at Harvard, Bernard was a Deputy Director at the Tan Tock Seng Hospital (TTSH-CDC) in Singapore and was responsible for medical manpower coordination during the SARS crisis. Prior to TTSH, he successfully co-founded and ran a contract research business, also in Singapore. In 1999, after serving as a physician, Dr. Peperstraete managed the HIV business unit at Bristol Myers & Squibb, Singapore.
Education, Personal, and Fellowship
Bernard was a Belgian American Education Foundation (BAEF) fellow at Harvard where he earned his MBA. He earned his MD at the Katholieke Universiteit Leuven in Belgium and his specialist diploma in Tropical Medicine at the Institut de Médecine Tropicale, also in Belgium. He was also nominated a Fulbright scholar.
Bernard is a member of Kauffman Fellows Class 11 and served his fellowship under mentor Sinclair Dunlop of MASA Life Science Ventures (MLSV) while working as a Principal at NGN Capital.